Abstract 170P
Background
The KRAS gene plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). This study aimed to investigate the frequency of KRAS mutations in patients with PDAC.
Methods
From 2020 to 2023, we retrospectively analyzed the KRAS status in 45 patients with PDAC. The distribution of clinical stages and the frequency of other mutations such as NRAS and BRCA2 were also evaluated.
Results
Among 45 patients, 30 (66.7%) had KRAS mutations, with the most frequent being G12D (50%), followed by G12V (26.6%). Q61K, G12A, A146T, G12R, and G12C mutations were less common. One patient with G12V mutation also had a BRCA2 mutation. In the mutated KRAS (mKRAS) group, 13 patients (43.3%) had metastatic disease, 12 (40%) had localized disease, and 5 (16.6%) had locally advanced disease. In the wild-type KRAS (wtKRAS) group, which consisted of 15 patients (33.3%), 7 (46.7%) had metastatic disease, 5 (33.3%) had localized disease, and 3 (20%) had locally advanced disease. One patient with wtKRAS also had a germline BRCA2 mutation. The distribution of clinical stages did not differ significantly between mKRAS and wtKRAS groups. NRAS mutation analysis was conducted in 41 patients, and no mutations were detected.
Conclusions
Our study revealed a high frequency of wtKRAS in patients with PDAC. Further investigation is needed to expound the clinical significance of KRAS status in this patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract